Table 3

Differences in the effect of time on outcomes between treatment groups for the following outcomes: health-related quality of life (measured by EQ-5D (0–1), coefficients from mixed effects linear regression), employment status (working for pay, ORs from mixed effects logistic regression), work productivity loss due to absenteeism, presenteeism and total work productivity loss (coefficient from mixed effects linear regression)

Natalizumab versus any other DMTsNatalizumab versus
category 1 DMTs
Natalizumab versus
category 2 DMTs
Natalizumab versus
category 3 DMTs
Natalizumab versus fingolimod
Health-related quality of life (EQ-5D index (0–1))Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)
 Interaction0.007 (−0.007 to 0.021)0.005 (−0.010 to 0.019)0.011 (−0.008 to 0.031)0.013 (−0.002 to 0.028)0.011 (−0.004 to 0.025)
 Natalizumab−0.002 (−0.015 to 0.012)0.002 (−0.001 to 0.014)−0.002 (−0.018 to 0.014)0.003 (−0.010 to 0.016)0.004 (−0.008 to 0.116)
 Comparison group0.008 (−0.013 to −0.003)−0.003 (−0.010 to 0.004)0.014 (−0.026 to −0.002)0.010 (−0.018 to −0.003)−0.006 (−0.014 to 0.001)
Employment status (working for pay vs not working)aOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
 Interaction0.85 (0.36 to 2.00)1.29 (0.49 to 3.43)0.45 (0.17 to 1.29)0.64 (0.23 to 1.76)0.63 (0.26 to 1.54)
 Natalizumab0.60 (0.27 to 1.36)0.64 (0.27 to 1.47)0.56 (0.25 to 1.26)0.58 (0.27 to 1.26)0.59 (0.28 to 1.27)
 Comparison group0.57 (0.25 to 1.28)0.49 (0.29 to 0.82)1.24 (0.64 to 2.40)0.79 (0.50 to 1.23)0.94 (0.59 to 1.49)
Total work productivity loss (absenteeism+presenteeism, 0%–100%)bCoefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)
 Interaction3.041 (−5.971 to −0.111)−2.042 (−4.447 to 0.363)−2.981 (−7.161 to 1.199)−3.106 (−6.749 to 0.538)−2.609 (−6.122 to 0.904)
 Natalizumab−1.647 (−4.374 to 1.080)−0.364 (−1.783 to 1.055)−2.210 (−5.381 to −12.757)−1.546 (−4.696 to 1.604)−0.996 (−3.983 to 1.991)
 Comparison group1.394 (0.347 to 2.441)1.628 (-0.087 to 3.344)0.771 (-1.068 to 2.506)1.559 (-0.250 to 3.369)1.613 (-0.224 to 3.450)
Work productivity loss due to absenteeism (0%–100%)bCoefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)
 Interaction2.256 (−4.179 to -0.333)−0.322 (2.176 to 0.336)2.836 (−5.604 to −0.068)3.052 (−5.403 to −0.701)2.934 (−5.222 to −0.647)
 Natalizumab−1.708 (−3.497 to 0.082)−0.920 (−1.607 to 0.377)2.117 (−4.218 to −0.016)2.321 (−4.441 to −0.401)2.347 (−4.282 to −0.412)
 Comparison group0.548 (−0.146 to 1.242)0.171 (−0.780 to 1.123)0.719 (−1.068 to 2.506)0.631 (−0.567 to 1.829)0.587 (−0.632 to 1.807)
Work productivity loss due to presenteeism (0%–100%)bCoefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)Coefficient (95% CI)
 Interaction−1.186 (−3.585 to 1.213)−1.330 (−3.390 to 0.731)0.021 (−3.449 to 3.491)−0.613 (−3.585 to 2.360)−0.377 (−3.221 to 2.468)
 Natalizumab−0.261 (−2.494 to 1.783)0.069 (−1.560 to 1.698)−0.172 (−2.810 to 2.446)0.443 (−2.127 to 3.014)0.710 (−5.381 to 0.961)
 Comparison group0.925 (0.068 to 1.783)1.398 (0.140 to 2.656)−0.193 (−2.433 to 2.046)1.056 (−0.419 to 2.531)1.087 (−0.926 to 3.469)
  • Interaction represents the difference in the effect of time (per year increase) on the outcome for natalizumab versus the comparison group.

  • a: Employment status analyses were restricted to those who were of working age (18–64 years, a total of 2420 observations, n=944 in 2015, n=703 in 2016 and n=773 in 2017).

  • b: Work productivity analysis was restricted to those who were working (a total of 1303 observations, n=505 in 2015, n=375 in 2016 and n=423 in 2017).

  • Data in bold indicate statistical significance, p<0.05.

  • EQ-5D, the European Quality of Life Five Dimension Questionnaire.